Overview of the latest treatments for castration-resistant prostate cancer.
作者： Mohamed Bishr , Fred Saad
关键词:
摘要: Over the past few years, we have developed an increased understanding of molecular mechanisms that underlie prostate cancer progression and castration resistance expanded our repertoire therapeutic options for castration-resistant (CRPC). Four new agents (cabazitaxel, abiraterone acetate, enzalutamide, radium-233) been shown to prolong overall survival in patients with CRPC postchemotherapy setting. Targeting androgen receptor pathway continues important role treatment CRPC, acetate enzalutamide being most exciting developments. Cabazitaxel is now considered standard-of-care second-line chemotherapy men metastatic (mCRPC). Bone-targeted therapy active area research, denosumab first bone-targeted agent able significantly delay appearance bone metastases radium-223 radiopharmaceutical improve mCRPC.
nature.com
europauomo.sk 参考文章(72)
Matthias M. Heck, Mark Thalgott, Margitta Retz, Petra Wolf, Tobias Maurer, Roman Nawroth, Georgios Hatzichristodoulou, Jürgen E. Gschwend, Hubert Kübler, Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer BJU International. ,vol. 110, pp. E635- E640 ,(2012) , 10.1111/J.1464-410X.2012.11364.X
Jorg Michels, Trina Montemurro, Nevin Murray, Christian Kollmannsberger, Kim Nguyen Chi, First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter? Cancer. ,vol. 106, pp. 1041- 1046 ,(2006) , 10.1002/CNCR.21695
Giuseppe Di Lorenzo, Carlo Buonerba, Adriana Faiella, Pasquale Rescigno, Mimma Rizzo, Riccardo Autorino, Sisto Perdonà, Nando Riccardi, Sarah Scagliorini, Florinda Scognamiglio, Daniele Masala, Matteo Ferro, Giovannella Palmieri, Michele Aieta, Alfredo Marinelli, Vincenzo Altieri, Sabino De Placido, Giacomo Cartenì, Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer BJUI. ,vol. 107, pp. 234- 239 ,(2011) , 10.1111/J.1464-410X.2010.09498.X
S P Balk, M E Taplin, T D Shuster, A M Fertig, G J Bubley, M A Fenton, G Kolvenbag, Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clinical Cancer Research. ,vol. 3, pp. 1383- 1388 ,(1997)
Frank Priou, Ivan Krakowski, Alain Zannetti, Laurence Thill, Philippe Beuzeboc, Jean-Christophe Eymard, Stéphane Oudard, Gwenaelle Gravis, Jean-Marc Ferrero, Christine Theodore, Florence Joly, Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJUI. ,vol. 106, pp. 974- 978 ,(2010) , 10.1111/J.1464-410X.2010.09296.X
Takeshi Ueda, Nicholas Bruchovsky, Marianne D. Sadar, Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways Journal of Biological Chemistry. ,vol. 277, pp. 7076- 7085 ,(2002) , 10.1074/JBC.M108255200
Fabio M. Paes, Aldo N. Serafini, Systemic metabolic radiopharmaceutical therapy in the treatment of metastatic bone pain Seminars in Nuclear Medicine. ,vol. 40, pp. 89- 104 ,(2010) , 10.1053/J.SEMNUCLMED.2009.10.003
Ramachandran Venkitaraman, Karen Thomas, Robert A. Huddart, Alan Horwich, David P. Dearnaley, Chris C. Parker, Efficacy of low-dose dexamethasone in castration-refractory prostate cancer BJU International. ,vol. 0, pp. 071017160927007- ??? ,(2007) , 10.1111/J.1464-410X.2007.07261.X
Alessandro Sciarra, Antonio Cardi, Franco Di Silverio, Antiandrogen Monotherapy: Recommendations for the Treatment of Prostate Cancer Urologia Internationalis. ,vol. 72, pp. 91- 98 ,(2004) , 10.1159/000075960
Julia Clemons, L Michael Glodé, Dexiang Gao, Thomas W Flaig, None, Low-dose diethylstilbestrol for the treatment of advanced prostate cancer Urologic Oncology: Seminars and Original Investigations. ,vol. 31, pp. 198- 204 ,(2013) , 10.1016/J.UROLONC.2010.12.004